Tags : Lebrikizumab

Eli Lilly to Acquire Dermira for $1.1B

Shots: Lilly acquires Dermira in all-cash transaction making total deal value ~$1.1B at $18.75/share representing premium of 86% to the 60-day volume-weighted average trading price of Dermira’s stock ending on January 9, 2020, with expected closure of agreement in Q1’20 The focus of the acquisition is to expand Eli Lilly’s immunology pipeline with the addition […]Read More

Almirall Signs an Option to License Agreement with Dermira to

Shots: Dermira to receive $30M upfront. Almira to get exclusive option to license rights for Dermira’s lebrikizumab to develop in dermatology & commercialize it in all indications in EU, with 45 days to exercise the option on basis of its P-IIb results If Almirall exercises its option, Dermira will receive $50M as option exercise fee, […]Read More